Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -2336.10% is 69% above its 2-year average of -7579.92%, near the high end of its 2-year range (-18789.07%–-856.34%).
74.15% above its 12-month average of -9037.26%.
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2024 (2024-12-31): -856.34%.
EBITDA MARGIN
-2336.10%
EBITDA MARGIN AVG TTM
-9037.26%
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+74.15%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Praxis Precision Medicines, Inc.
Market Cap
$7.81B
EBITDA Margin
-2336.10%
TTM Avg
-9037.26%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.76B
EBITDA Margin
8.34%
TTM Avg
-21.08%
3Y Avg
-58.51%
5Y Avg
-29.82%
Market Cap
$7.63B
EBITDA Margin
-684.44%
TTM Avg
-1767.79%
3Y Avg
-2575.30%
5Y Avg
-1786.18%
Market Cap
$7.99B
EBITDA Margin
20.05%
TTM Avg
16.44%
3Y Avg
-1944.65%
5Y Avg
-32112.59%
Market Cap
$7.61B
EBITDA Margin
36.33%
TTM Avg
34.52%
3Y Avg
30.06%
5Y Avg
28.41%
Market Cap
$7.61B
EBITDA Margin
-92.07%
TTM Avg
-49.82%
3Y Avg
-47.83%
5Y Avg
-47.83%
Market Cap
$7.31B
EBITDA Margin
-38.32%
TTM Avg
-51.29%
3Y Avg
-52.67%
5Y Avg
-38.88%
Market Cap
$8.38B
EBITDA Margin
-3.14%
TTM Avg
-1.08%
3Y Avg
-5.02%
5Y Avg
-19.32%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Praxis Precision Medicines, Inc. (PRAX) | $7.81B | -2336.10% | -9037.26% | N/A | N/A |
| Caris Life Sciences, Inc. (CAI)vs › | $7.76B | 8.34% | -21.08% | -58.51% | -29.82% |
| Cytokinetics, Incorporated (CYTK)vs › | $7.63B | -684.44% | -1767.79% | -2575.30% | -1786.18% |
| TG Therapeutics, Inc. (TGTX)vs › | $7.99B | 20.05% | 16.44% | -1944.65% | -32112.59% |
| HealthEquity, Inc. (HQY)vs › | $7.61B | 36.33% | 34.52% | 30.06% | 28.41% |
| Hinge Health, Inc. (HNGE)vs › | $7.61B | -92.07% | -49.82% | -47.83% | -47.83% |
| Ionis Pharmaceuticals, Inc. (IONS)vs › | $7.31B | -38.32% | -51.29% | -52.67% | -38.88% |
| Oscar Health, Inc. (OSCR)vs › | $8.38B | -3.14% | -1.08% | -5.02% | -19.32% |
| Alkermes plc (ALKS)vs › | $6.99B | 19.05% | 23.95% | 20.94% | 15.97% |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.67B | 14.74% | -8194.33% | -4134.44% | -2789.78% |
Gross Margin
0.0%
EBITDA Margin
-2336.1%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2024-12-31 | -856.34% |
| 2024-09-30 | -18789.07% |
| 2024-06-30 | -10470.87% |
| 2024-03-31 | -9692.34% |
| 2023-12-31 | -5377.67% |
| 2023-09-30 | -5428.85% |
| 2023-06-30 | -4462.74% |
| 2023-03-31 | -5561.49% |
